<DOC>
	<DOCNO>NCT02804191</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Placebo-Controlled , Parallel Group , Multi-Center Study Evaluate Efficacy Safety LO2A Eye Drops Patients Moderate Severe Conjunctivochalasis</brief_summary>
	<brief_title>Evaluate Efficacy Safety LO2A Eye Drops Patients With Moderate Severe Conjunctivochalasis</brief_title>
	<detailed_description>Phase 2 , randomize , placebo-controlled , parallel group , study 62 adult patient moderate severe CCh . Eligible patient randomly assign 1:1 ratio one two treatment group , LO2A placebo , stratify LIPCOF grade baseline . This study 4 visit , consist screen period 2 week 3-month treatment period ( topical , OU , QID application eye drop ) .</detailed_description>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Male female race ≥ 18 year age . 2 . Willing able provide voluntary write informed consent . 3 . Moderate severe conjunctivochalasis define : LIPCOF score ≥ 2 ; Lissamine green conjunctival stain score ≥ 5 accord National Eye Institute/Industry Workshop report . 4 . Willing able adhere study visit schedule protocol requirement . 1 . Subject concurrent , uncontrolled medical condition , psychiatric illness could place him/her unacceptable risk , include , limited : Subject diagnose treat another malignancy within 3 year screen , except situ malignancy , lowrisk prostate , skin cervix cancer curative therapy . A comorbid condition , view Investigators , render subject high risk treatment complication . 2 . Subjects pterygium . 3 . Subjects active , allergic keratoconjunctivitis , conjunctivitis infectious origin . 4 . Subjects blepharitis require treatment . 5 . Subjects history surgery affect eye surface , well eye injury within 3 month screen . 6 . Subjects currently use topical ophthalmic treatment ( include medication glaucoma ) overthecounter ( OTC ) solution , artificial tear , gel scrub , discontinue medication duration trial . 7 . Subjects use follow medication treatment : LASIK PRK surgery within 12 month Visit 1 . Use contact lens within 7 day Visit 1 . Punctal plug insertion within 30 day Visit 1 . Use topical systemic cyclosporine within 30 day Visit 1 . Use medication know cause ocular drying ( e.g . antihistamine , sleep aid , etc . ) , unless stable dose , within 30 day Visit 1 . 8 . Known hypersensitivity sodium hyaluronate LO2A excipients ( glycerol Carbomer 981 ) . 9 . Active abuse alcohol drug . 10 . Any condition , opinion Investigator , would place patient unacceptable risk participate study protocol . 11 . Participation clinical trial investigational ( unapproved ) drug device within 1 month prior screen schedule receive another investigational drug device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>